Neoprobe, Cardinal Health ink terms for Lymphoseek distribution:
This article was originally published in Clinica
Manufacturer of oncology and cardiovascular products Neoprobe has signed a non-binding term sheet with Cardinal Health for the exclusive US marketing and distribution rights to its Lymphoseek radioactive lymphatic mapping targeting agent. Cardinal Health, headquartered in Dublin, Ohio, will provide Neoprobe with a distribution network of more than 150 nuclear pharmacies, and its wholesale distribution operations to in-hospital nuclear pharmacies. Neoprobe, also located in Dublin, Ohio, is developing Lymphoseek for use with hand-held gamma detection devices, and is preparing to submit a phase III multicenter clinical trial to the FDA.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.